Legend Biotech Corp reports results for the quarter ended June 30 - Earnings Summary

• Legend Biotech Corp LEGN.OQ reported a quarterly adjusted loss of 68 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -10 cents. The mean expectation of fourteen analysts for the quarter was for a loss of 15 cents per share. Wall Street expected results to range from -24 cents to -4 cents per share.

• Revenue rose 36.7% to $255.06 million from a year ago; analysts expected $228.99 million.

• Legend Biotech Corp's reported EPS for the quarter was a loss of 68 cents​.

• The company reported a quarterly loss of $125.38 million.

• Legend Biotech Corp shares had risen by 4.3% this quarter and gained 13.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 24.7% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Legend Biotech Corp is $75.00, about 50.7% above its last closing price of $37.00

This summary was machine generated from LSEG data August 11 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)